Intended for healthcare professionals

Letters Warfarin and atrial fibrillation

Authors’ reply to Williams

BMJ 2015; 350 doi: (Published 24 March 2015) Cite this as: BMJ 2015;350:h1582
  1. Min Jun, postdoctoral fellow1,
  2. Brenda R Hemmelgarn, professor1
  1. 1Department of Medicine, Division of Nephrology, University of Calgary, AB, Canada T2N 2T9
  1. mjun{at}

Regarding our use of the number needed to treat to harm (NNH),1 2 we aimed to determine the association between kidney function (different stages of chronic kidney disease) and the rate of major bleeding (safety of warfarin therapy) in older adults with atrial fibrillation, specifically those starting warfarin.

We focused on assessing the risk of major bleeding in these patients because reluctance to use warfarin mostly relates to uncertainties about its safety in this setting, and data on its use …

View Full Text

Log in

Log in through your institution


* For online subscription